Cargando…

Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies—Current Research and Clinical Approaches

Multiple myeloma (MM) accounts for 10% of all hematological malignancies, and it is the second most common hematological neoplasm for which chemotherapy is an important pharmacological treatment. High dose melphalan followed by autologous stem cell transplantation remains the standard of treatment f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poczta, Anastazja, Rogalska, Aneta, Marczak, Agnieszka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123041/ https://www.ncbi.nlm.nih.gov/pubmed/33922721 http://dx.doi.org/10.3390/jcm10091841

Ejemplares similares

Synthesis and In Vitro Activity of Novel Melphalan Analogs in Hematological Malignancy Cells
por: Poczta, Anastazja, et al.
Publicado: (2022)

Newly Synthesized Melphalan Analogs Induce DNA Damage and Mitotic Catastrophe in Hematological Malignant Cancer Cells
por: Poczta, Anastazja, et al.
Publicado: (2022)

Antileukemic activity of novel adenosine derivatives
por: Poczta, Anastazja, et al.
Publicado: (2019)

Chemical modification of melphalan as a key to improving treatment of haematological malignancies
por: Gajek, Arkadiusz, et al.
Publicado: (2020)

Current Implications of microRNAs in Genome Stability and Stress Responses of Ovarian Cancer
por: Gajek, Arkadiusz, et al.
Publicado: (2021)

The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2022)

The Safety Profile of Concurrent Therapy for Multiple Myeloma in the Modern Era
por: Resende Salgado, Lucas, et al.
Publicado: (2018)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019)

Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration
por: Ge, Qunfang, et al.
Publicado: (2022)

Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer
por: Gralewska, Patrycja, et al.
Publicado: (2020)

Retracted: Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma
por: Morabito, Fortunato, et al.
Publicado: (2021)

Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
por: Srour, Samer A., et al.
Publicado: (2021)

Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma
por: Gillich, Cédric, et al.
Publicado: (2023)

Influence of PJ34 on the genotoxicity induced by melphalan in human multiple myeloma cells
por: Xiong, Ting, et al.
Publicado: (2015)

Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells
por: Gourzones, Claire, et al.
Publicado: (2019)

TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan
por: Håland, Erling, et al.
Publicado: (2021)

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Rodriguez, Tulio E., et al.
Publicado: (2016)

Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
por: Byun, Ja Min, et al.
Publicado: (2018)

Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines
por: Gralewska, Patrycja, et al.
Publicado: (2021)

Olaparib-Resistant BRCA2(MUT) Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival
por: Biegała, Łukasz, et al.
Publicado: (2023)

Repeat administration of high dose melphalan in relapsed myeloma.
por: Mansi, J. L., et al.
Publicado: (1993)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Functional analysis of the involvement of apurinic/apyrimidinic endonuclease 1 in the resistance to melphalan in multiple myeloma
por: Xie, Jiayin, et al.
Publicado: (2014)

Comparison of two melphalan protocols and evaluation of outcome and prognostic factors in multiple myeloma in dogs
por: Fernández, Ricardo, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma
por: Cao, Yaohua, et al.
Publicado: (2021)

Hyperglycemia-Associated Dysregulation of O-GlcNAcylation and HIF1A Reduces Anticancer Action of Metformin in Ovarian Cancer Cells (SKOV-3)
por: Rogalska, Aneta, et al.
Publicado: (2018)

Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma
por: Park, Songyi, et al.
Publicado: (2021)

Radiotherapy in Combination with Systemic Therapy for Multiple Myeloma—A Critical Toxicity Evaluation in the Modern Treatment Era
por: Oertel, Michael, et al.
Publicado: (2023)

A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients.
por: Belch, A., et al.
Publicado: (1988)

Novel oxazolinoanthracyclines as tumor cell growth inhibitors—Contribution of autophagy and apoptosis in solid tumor cells death
por: Rogalska, Aneta, et al.
Publicado: (2018)

The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous BRCA(MUT) and BRCA(WT) Ovarian Cancer Cells
por: Gralewska, Patrycja, et al.
Publicado: (2022)

Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy
por: Chakraborty, Rajshekhar, et al.
Publicado: (2021)

Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life study
por: Debureaux, Pierre-Edouard, et al.
Publicado: (2022)

Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
por: Azarm, Taleb, et al.
Publicado: (2012)

Comparable Outcomes using Propylene Glycol-Free Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2018)

Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105)
por: Maruyama, Dai, et al.
Publicado: (2020)

Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma
por: Nath, Christa Ellen, et al.
Publicado: (2022)

The Impact of Renal Impairment in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation With Melphalan Conditioning
por: Ursu, Sorana G., et al.
Publicado: (2023)

Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial
por: Farag, Sarah, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3jcrd43vjkppv5ffuve63sr9ai